ATE555814T1 - Radioaktive mittel für die in vivo pet-bildgebung von ccr5 - Google Patents
Radioaktive mittel für die in vivo pet-bildgebung von ccr5Info
- Publication number
- ATE555814T1 ATE555814T1 AT07848610T AT07848610T ATE555814T1 AT E555814 T1 ATE555814 T1 AT E555814T1 AT 07848610 T AT07848610 T AT 07848610T AT 07848610 T AT07848610 T AT 07848610T AT E555814 T1 ATE555814 T1 AT E555814T1
- Authority
- AT
- Austria
- Prior art keywords
- ccr5
- pet imaging
- radioactive agents
- imaging
- vivo pet
- Prior art date
Links
- 238000003384 imaging method Methods 0.000 title abstract 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 title 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 title 1
- 238000001727 in vivo Methods 0.000 title 1
- 230000002285 radioactive effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000009410 Chemokine receptor Human genes 0.000 abstract 1
- 108050000299 Chemokine receptor Proteins 0.000 abstract 1
- 238000002059 diagnostic imaging Methods 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 230000003827 upregulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0625523.6A GB0625523D0 (en) | 2006-12-21 | 2006-12-21 | In vivo imaging agents |
| PCT/GB2007/004880 WO2008075040A2 (en) | 2006-12-21 | 2007-12-19 | In vivo imaging agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE555814T1 true ATE555814T1 (de) | 2012-05-15 |
Family
ID=37734613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07848610T ATE555814T1 (de) | 2006-12-21 | 2007-12-19 | Radioaktive mittel für die in vivo pet-bildgebung von ccr5 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20110129419A1 (enExample) |
| EP (1) | EP2125038B1 (enExample) |
| JP (1) | JP5431954B2 (enExample) |
| CN (1) | CN101678129B (enExample) |
| AT (1) | ATE555814T1 (enExample) |
| ES (1) | ES2384002T3 (enExample) |
| GB (1) | GB0625523D0 (enExample) |
| WO (1) | WO2008075040A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7344702B2 (en) | 2004-02-13 | 2008-03-18 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardial perfusion imaging |
| ES2804801T3 (es) | 2006-12-26 | 2021-02-09 | Lantheus Medical Imaging Inc | Ligandos para la formación de imágenes de la inervación cardíaca |
| EP2036578A1 (en) * | 2007-09-13 | 2009-03-18 | Bayer Schering Pharma Aktiengesellschaft | Diagnostic agents for positron emission imaging using F-18 radio labeled amino-alcohols |
| KR101709372B1 (ko) | 2010-02-08 | 2017-02-22 | 랜티우스 메디컬 이메징, 인크. | 조영제 및 이의 중간체를 합성하는 방법 및 장치 |
| KR20170042373A (ko) * | 2010-05-11 | 2017-04-18 | 랜티우스 메디컬 이메징, 인크. | 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템 |
| CN101921224B (zh) * | 2010-05-21 | 2012-01-18 | 中国人民解放军军事医学科学院生物工程研究所 | 1-（3-氨基丙基）哌嗪-4-氨基酰胺类化合物及其制备方法与应用 |
| WO2012074840A2 (en) * | 2010-11-22 | 2012-06-07 | The General Hospital Corporation | Compositions and methods for in vivo imaging |
| EP3567029A1 (en) | 2011-09-09 | 2019-11-13 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| US20180036312A1 (en) * | 2016-08-02 | 2018-02-08 | ISI Life Sciences Inc. | Novel Scaffolds for Intracellular Compound Delivery for the Detection of Cancer Cells |
| WO2018026965A1 (en) | 2016-08-02 | 2018-02-08 | Isi Life Sciences, Inc. | Compositions and methods for detecting cancer cells in a tissue sample |
| US10753942B2 (en) | 2017-05-15 | 2020-08-25 | Indicator Systems International, Inc. | Methods to detect remnant cancer cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002521436A (ja) * | 1998-07-28 | 2002-07-16 | スミスクライン・ビーチャム・コーポレイション | 置換アニリド化合物および方法 |
| TR200103214T2 (tr) * | 1999-05-04 | 2002-03-21 | Schering Corporation | CCR5 antagonistleri olarak yararlì piperazin trevleri. |
| AR025884A1 (es) * | 1999-10-01 | 2002-12-18 | Takeda Pharmaceutical | Compuestos de amina ciclica, su produccion y su uso |
| PT1236726E (pt) * | 1999-12-03 | 2005-04-29 | Ono Pharmaceutical Co | Derivados de triazaespiro[5.5]undecano e farmacos que os contem como ingrediente activo |
| GB0005642D0 (en) * | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
| HUP0302966A2 (hu) * | 2000-07-31 | 2003-12-29 | Smithkline Beecham P.L.C. | Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| UY27003A1 (es) | 2000-11-06 | 2002-07-31 | Schering Ag | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
| GB0115929D0 (en) | 2001-06-29 | 2001-08-22 | Nycomed Amersham Plc | Solid-phase electrophilic fluorination |
| GB0115927D0 (en) | 2001-06-29 | 2001-08-22 | Nycomed Amersham Plc | Solid-phase nucleophilic fluorination |
| SE0103819D0 (sv) * | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| GB0127547D0 (en) * | 2001-11-16 | 2002-01-09 | Astrazeneca Ab | Chemical compounds |
| CN101189339A (zh) * | 2005-03-22 | 2008-05-28 | 美得思达健康有限公司 | 诊断和治疗心血管疾病的递送系统和方法 |
-
2006
- 2006-12-21 GB GBGB0625523.6A patent/GB0625523D0/en not_active Ceased
-
2007
- 2007-12-19 EP EP07848610A patent/EP2125038B1/en not_active Not-in-force
- 2007-12-19 AT AT07848610T patent/ATE555814T1/de active
- 2007-12-19 US US12/519,398 patent/US20110129419A1/en not_active Abandoned
- 2007-12-19 JP JP2009542206A patent/JP5431954B2/ja not_active Expired - Fee Related
- 2007-12-19 CN CN2007800466940A patent/CN101678129B/zh not_active Expired - Fee Related
- 2007-12-19 ES ES07848610T patent/ES2384002T3/es active Active
- 2007-12-19 WO PCT/GB2007/004880 patent/WO2008075040A2/en not_active Ceased
-
2012
- 2012-12-18 US US13/718,135 patent/US20130129626A1/en not_active Abandoned
- 2012-12-18 US US13/718,124 patent/US20130129625A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130129626A1 (en) | 2013-05-23 |
| WO2008075040A3 (en) | 2009-11-05 |
| EP2125038B1 (en) | 2012-05-02 |
| GB0625523D0 (en) | 2007-01-31 |
| CN101678129A (zh) | 2010-03-24 |
| US20130129625A1 (en) | 2013-05-23 |
| EP2125038A2 (en) | 2009-12-02 |
| US20110129419A1 (en) | 2011-06-02 |
| CN101678129B (zh) | 2013-01-16 |
| ES2384002T3 (es) | 2012-06-28 |
| JP2010513441A (ja) | 2010-04-30 |
| WO2008075040A2 (en) | 2008-06-26 |
| JP5431954B2 (ja) | 2014-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE555814T1 (de) | Radioaktive mittel für die in vivo pet-bildgebung von ccr5 | |
| CY1121327T1 (el) | Τροποποιημενα αντισωματα anti-il-23p19 | |
| PH12021550756A1 (en) | Compositions and methods for treating and/or preventing cardiovascular disease | |
| UY31114A1 (es) | Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos | |
| MY153198A (en) | Inhibitors of protein aggregation | |
| MA33839B1 (fr) | Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs | |
| MA31231B1 (fr) | Anticorps anti-robo4 et utilisations de ceux-ci | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| EA201590833A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
| MX379016B (es) | Composiciones y metodos para tratar enfermedad de gaucher. | |
| EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
| EP2546649A3 (en) | Biomarkers for fatty liver disease and methods using the same | |
| MA34057B1 (fr) | Compositions et methodes pour le diagnostic et le traitement d'une tumeur | |
| MY148484A (en) | Caspase imaging probes | |
| GB2437009A (en) | Ranking system | |
| EP2318834A4 (en) | USE OF BACTERIAL BETA LACTAMASE FOR IN VITRO DIAGNOSTICS AND IN VIVO IMAGING, DIAGNOSTICS AND THERAPEUTICS | |
| EP2478901A3 (en) | Neurogenic compounds | |
| EP3441467A3 (en) | Biotin complexes for treatment and diagnosis of alzheimer's disease | |
| NO20071613L (no) | Forbindelser for myokardial perfusjons-billeddannelse | |
| MY155340A (en) | Use of cathepsin c | |
| MA34291B1 (fr) | Compositions et méthodes de diagnostic et de traitement d'une tumeur | |
| MA29587B1 (fr) | Compositions et methodes de diagnostic et de traitement de tumeur | |
| ATE552268T1 (de) | Optimierte adhäsin-fragmente und entsprechende nanopartikel | |
| ATE442382T1 (de) | Ein die mam-domäne enthaltendes protein | |
| FR2889805B1 (fr) | Equipement pour salle medicalisee, notamment pour cabinet de soins dentaires |